In this guide
What is the tesamorelin and ipamorelin stack?
The tesamorelin and ipamorelin stack, usually called "tesa/ipa", pairs a prescription medicine that raises growth hormone with an unapproved peptide that raises it through a second route. People use it mainly for belly fat, sleep and body composition. Premixed vials are sold as Hulk, Phoenix, Bimorelin and Triad-GH. No study has tested the pair together. [10], [11], [3], [5]
Tesamorelin is approved in the United States as EGRIFTA for one use: excess belly fat in adults with HIV and lipodystrophy. Ipamorelin has never been approved anywhere. People use separate vials, injected together or at different times, or one premixed vial that fixes the amount of each. [10], [21], [22]
In community education groups, many tesamorelin reports involve ipamorelin, and most people on the pair also take a GLP-1 drug such as tirzepatide or retatrutide, so reported effects belong to whole regimens. Each part has its own full guide, linked above.
What's in it, and what else is it called?
The stack has two parts: tesamorelin, a lab-made copy of GHRH (growth-hormone-releasing hormone, the brain's signal to release growth hormone), and ipamorelin, which acts at the ghrelin receptor, a second switch for the same release. One blend adds a third part, CJC-1295, another lab-made GHRH. [10], [11], [7]
| Name | Type | What it usually contains | Where sources disagree |
|---|---|---|---|
| Tesa/Ipa | Community name | Tesamorelin and ipamorelin taken together, from separate vials or one premixed vial [12] | The everyday name for the pair, also written Tesa-Ipa. |
| Tesamorelin/ipamorelin blend | Premixed blend | Both peptides in one vial; listed amounts include tesamorelin 10 mg + ipamorelin 3 mg, 5 mg + 5 mg, 10 mg + 10 mg and 11 mg + 6 mg [1], [2], [13], [14] | The pair is fixed but the ratio is not: from 1:1 to about 6:1 by mass across products. Also sold as "2X" and "SomatoPulse". [2], [5], [15], [4] Tesa/Ipa blend details |
| Hulk (The Hulk, Hulk XL, Hulk nasal spray) | Premixed blend | Tesamorelin 6 mg + ipamorelin 3 mg per vial (9 mg in total); the same brand lists Hulk XL at 13 mg + 3 mg (16 mg) and a 6 mg + 3 mg nasal spray [3], [4], [48] | One brand's name (Pure Tested Peptides), also sold through at least one other shop. Other sellers use Hulk for CJC-1295 with ipamorelin, without DAC (5 mg + 5 mg) or with DAC (10 mg + 10 mg, or 20 mg in total), and one for BPC-157 with TB-500. [3], [48], [16], [49], [17], [18] Hulk details |
| Phoenix | Premixed blend | Tesamorelin 12 mg + ipamorelin 2 mg per vial (14 mg in total) [5] | The seller says an earlier 10 mg + 5 mg version was discontinued. Another seller's "Tri-Blend (Phoenix)" is a KPV, TB-500 and BPC-157 recovery blend. [5], [19] Phoenix details |
| Bimorelin | Premixed blend | Tesamorelin 10 mg + ipamorelin 3 mg per vial, as quoted in an FDA warning letter [6] | FDA called it an unapproved new drug in August 2026. [6] Bimorelin details |
| Triad-GH | Premixed blend | Tesamorelin 6 mg + ipamorelin 3 mg + CJC-1295 without DAC 3 mg per vial (12 mg in total) [7] | One seller's product. It adds a second GHRH-type peptide to tesamorelin. [7] Triad-GH details |
A nickname does not fix what is in the vial. At some sellers, Hulk is tesamorelin with ipamorelin, and Phoenix also names a recovery blend; see Hulk and Phoenix. "Tesa/CJC/Ipa" and "GHRH/GHRP blend" are descriptions, not fixed formulas, and names whose contents we could not confirm on a public page are not listed. Only the label's amount of each peptide tells you what a dose contains. In community education groups, people mostly just say "tesa/ipa".
What is in each blend in this stack?
Premixed tesamorelin and ipamorelin vials are sold mostly as a plain "tesa/ipa blend", and also as Hulk, Phoenix and Bimorelin; Triad-GH adds CJC-1295. The ratio runs from 1:1 to 6:1 between products, and no blend has been tested in people.
Amounts below are what labels state. They are not doses, and not proof of contents. The sellers of the named blends give no dosing. [3], [5], [7]
Tesa/Ipa blend
Premixed vials of tesamorelin and ipamorelin sold simply under the two peptide names, with no brand nickname. The 10 mg + 3 mg vial is the one dosing pages build their schedules around.
| Vial | Tesamorelin | Ipamorelin | Sources |
|---|---|---|---|
| 13 mg (most common on dosing pages) | 10 mg | 3 mg | [1], [23], [24] |
| 10 mg and 20 mg | 5 mg or 10 mg | 5 mg or 10 mg | [2], [13] |
| 15 mg ("2X", clinic supply) | 10 mg | 5 mg | [15] |
| 17 mg | 11 mg | 6 mg | [14] |
- Where sellers disagree: on the ratio. A page titled "5mg/10mg" means two vial sizes with equal amounts of each, not a 1:2 mix. The same 10 mg + 3 mg formula is also sold as "SomatoPulse". [2], [4]
- Stated amounts: protocol pages for the 10 mg + 3 mg vial give 1 mg of tesamorelin with 300 mcg of ipamorelin, once in the evening; see the combination schedules. [23], [24]
- Regulators: FDA's August 2026 warning letter to one seller named its "Tesamorelin Ipamorelin Blend" an unapproved new drug. [25]
Hulk
One brand's name for this pair, also sold by a reseller, with more ipamorelin per milligram of tesamorelin than the common 10 mg + 3 mg vial: 500 mcg with each 1 mg, against 300 mcg. [3], [48]
| Product | Tesamorelin | Ipamorelin | Sources |
|---|---|---|---|
| The Hulk (9 mg vial) | 6 mg | 3 mg | [3], [48] |
| Hulk XL (16 mg vial) | 13 mg | 3 mg | [4], [48] |
| Hulk nasal spray | 6 mg | 3 mg | [4], [48] |
- Where sellers disagree: on everything. Other sellers' Hulk is CJC-1295 without DAC 5 mg + ipamorelin 5 mg, CJC-1295 with DAC 10 mg + ipamorelin 10 mg, a 20 mg CJC-1295 with DAC and ipamorelin set, or BPC-157 15 mg + TB-500 15 mg. [16], [49], [17], [18]
- The nasal spray: no study supports nasal use of either peptide, and tesamorelin's label covers subcutaneous injection only. [10]
- Stated amounts and regulators: the Hulk pages give no dose, and no notice we found names Hulk.
- Related stacks: the CJC-1295 and ipamorelin stack and the healing and recovery stack cover the other Hulks.
Phoenix
The lowest ipamorelin share we found: about 167 mcg with each 1 mg of tesamorelin.
| Version | Tesamorelin | Ipamorelin | Sources |
|---|---|---|---|
| Current (14 mg vial) | 12 mg | 2 mg | [5] |
| Earlier, discontinued (15 mg vial) | 10 mg | 5 mg | [5] |
- Where sellers disagree: another seller's "Tri-Blend (Phoenix)" is KPV, TB-500 and BPC-157 at 10 mg each, covered in the healing and recovery stack. [19]
- Stated amounts and regulators: the seller gives no dose, and no notice we found names Phoenix.
Bimorelin
Known mainly from FDA's warning letter of August 24, 2026, which quotes the seller's page describing a blend of tesamorelin 10 mg and ipamorelin 3 mg, the same ratio as the common tesa/ipa vial, and calls BIMORELIN an unapproved new drug. [6]
Triad-GH
Tesamorelin 6 mg + ipamorelin 3 mg + CJC-1295 without DAC 3 mg (12 mg in total), from one seller. With each 1 mg of tesamorelin come 500 mcg of ipamorelin and 500 mcg of CJC-1295. [7]
- What CJC-1295 is claimed to add: a second GHRH signal, on the same receptor as tesamorelin. Educators in community education groups almost all advise against two GHRH-type peptides together. Most people who make antibodies to tesamorelin make some that also recognize natural GHRH, so an allergy to one may carry over to the other. [10]
- What CJC-1295's guide found: it is not approved, and FDA could not find any study of the version without DAC in people. [20]
- Stated amounts and regulators: the seller says it provides no dosing guidance. FDA's 2024 review of CJC-1295 noted three-part CJC-1295, tesamorelin and ipamorelin powders on sale, with no clinical data. [7], [20]
- Related stacks: the CJC-1295 and ipamorelin stack.
Why do people combine tesamorelin and ipamorelin?
People combine them hoping two different growth-hormone signals add up to a bigger pulse, with tesamorelin aimed at belly fat and ipamorelin at sleep and recovery. That rationale comes from short studies of related peptides, not proof for this pair. [8], [12]
- Two receptors. Tesamorelin acts at the GHRH receptor and ipamorelin at the ghrelin receptor, so each sends its own signal to the pituitary gland. [10], [11]
- Old studies of other peptides. In 1990, single IV doses of full-length GHRH with GHRP-6, a related peptide covered in the classic GH releasers stack, released more growth hormone in 18 healthy men than expected from each alone. [8] A 1995 test in eight men with GHRP-2 found no more than the two added together. [9] A 2009 study of 47 men found the combined effect was smaller in older men and in men with more belly fat. [26] None used tesamorelin or ipamorelin, repeated doses, or measured fat or safety.
- Different goals. Protocol pages pitch tesamorelin for deep belly fat and ipamorelin for sleep and recovery. [12], [27] In community education groups, many hope the pair protects muscle during GLP-1 weight loss; the GLP-1 support stack covers that pairing.
What does the evidence show?
No trial, animal study or case report has tested tesamorelin and ipamorelin together. Tesamorelin has solid trial evidence for one use; ipamorelin has almost none.
Tesamorelin
Two placebo-controlled trials in 816 adults with HIV and excess belly fat: deep belly (visceral) fat fell about 15% more than on placebo over 26 weeks, body weight did not change, and the fat came back within about 3 months of stopping. The trials enrolled only adults with HIV. [28], [10] Full tesamorelin evidence
Ipamorelin
The human studies gave it into a vein: single doses in healthy men, and a week of doses after bowel surgery in 114 adults, where it did no better than placebo. FDA found no human safety data for subcutaneous injection, the way people use it. [29], [30], [11] Full ipamorelin evidence
The combination
- Nothing tested. Searches of PubMed and ClinicalTrials.gov in September 2026 found no trial, animal study or case report of tesamorelin with ipamorelin, or with any related ghrelin-type peptide; the PubMed results were reviews.
- Related peptides only. The IV studies of other peptides described above are the only human data on combining the two kinds of signal. [8], [9], [26]
- Regulators have seen the products, not data. FDA's 2026 warning letters named two tesa/ipa blends, and its 2024 CJC-1295 review noted a three-part blend on sale. Neither reports any clinical data on the combination. [25], [6], [20]
How do the tesamorelin and ipamorelin protocols line up?
| Part | Amount each time | Frequency | Total per day or week | Duration | Source |
|---|---|---|---|---|---|
| Tesamorelin · typical labeled dose (EGRIFTA WR) | 1.28 mg | Once daily | 1.28 mg a day | Ongoing; reconsider if belly fat has not fallen | [10] |
| Tesamorelin · research vials, off label | 1 mg | Once daily at bedtime | 7 mg a week | At least 12–16 weeks | [31] |
| Ipamorelin | 100 mcg | Once daily at bedtime | 100 mcg a day | 8–12 weeks | [32] |
These rows come from each part's own guide; ipamorelin sources most often give 100–300 mcg per injection. They are not a stack protocol: no source tested them together, and the label dose applies to EGRIFTA, not research vials. [10], [32]
Schedules published for the combination
Each row is a complete schedule from one page, with that page's amounts kept together. Across these pages, most pair about 1 mg of tesamorelin with 100–300 mcg of ipamorelin at bedtime on an empty stomach; several use 5 days on and 2 off, and courses run 8 weeks to 6 months. [12], [23], [27], [33], [34]
| Source type | Tesamorelin | Ipamorelin | When | Duration | Source |
|---|---|---|---|---|---|
| Clinic, compounded 2:1 vial | 1 mg in month 1, then 1.5 mg | 0.5 mg, then 0.75 mg | Before bed, 2 hours after food, 5 days on and 2 off | 3 months | [33] |
| Clinic blog | About 1 mg | About 100–300 mcg | Before bed on an empty stomach, often 5 days on and 2 off | 8–12 weeks, then a break | [12] |
| Dosing page, 10 mg + 3 mg vial | 1 mg | 300 mcg | Once daily in the evening, 5 days on and 2 off | 8 weeks on, 8 weeks off | [23] |
| Dosing page, 5 mg + 5 mg vial | 167, 333, 500, then 667 mcg | The same as tesamorelin at each step | Once daily, usually in the evening | Weeks 1–2, 3–4, 5–8 and 9–16, then 4–8 weeks off | [24] |
| Dosing page | 1–2 mg | 100–300 mcg | Once daily before bed, more than 2 hours after food | 3–6 months, then 1–2 months off | [27] |
| Dosing page | 1–2 mg | 100–200 mcg | Together, daily before bed, fasted | 60–90 days | [34] |
| Dosing page, staggered | 1–2 mg in the morning | 100–200 mcg at bedtime | Tesamorelin in the morning, ipamorelin at bedtime | 12–26 weeks | [22] |
What each blend delivers with 1 mg of tesamorelin
Arithmetic from each vial's listed amounts, not a dose.
| Blend (tesamorelin + ipamorelin per vial) | Ipamorelin with each 1 mg of tesamorelin | Source |
|---|---|---|
| Phoenix (12 mg + 2 mg) | About 167 mcg | [5] |
| Hulk XL (13 mg + 3 mg) | About 230 mcg | [4] |
| Tesa/Ipa, SomatoPulse or Bimorelin (10 mg + 3 mg) | 300 mcg | [1], [6] |
| The Hulk (6 mg + 3 mg) or 2X (10 mg + 5 mg) | 500 mcg | [3], [15] |
| Triad-GH (6 mg + 3 mg + CJC-1295 3 mg) | 500 mcg, plus 500 mcg of CJC-1295 | [7] |
| Equal blends (5 mg + 5 mg or 10 mg + 10 mg) | 1,000 mcg | [2], [13] |
How people line them up
Most pages put both in one bedtime injection on an empty stomach; one gives tesamorelin in the morning and ipamorelin at bedtime. [34], [27], [22] In community education groups, people who sleep badly or cannot be fasted at night on a GLP-1 drug move tesamorelin to the morning, and some start tesamorelin alone for a week or two so a reaction can be traced. Nobody has compared these approaches.
These schedules come from protocol sources for each part; no trial has tested this combination.
Where these numbers come from
The first table copies each part's reference protocol from its Doserly guide, citing the original label and protocol pages those guides verified. The combination schedules each come from one page and are shown as published, not merged. The blend table is arithmetic from listed vial contents. We did not combine one page's tesamorelin amount with another page's ipamorelin amount. [10], [31], [32], [33], [23], [24]
Left out: pages without a course length, a calculator, a chart whose numbers contradicted each other, an influencer page whose blend and separate-vial schedules did not match, and a provider chart that runs to 3 mg of tesamorelin, above any labeled dose. [15]
Plan it once. Two peptides on different days, times or phases are easy to mix up.
What are the overlapping risks and interactions?
Both parts raise growth hormone, so their growth-hormone side effects can add up, and the pair has never been safety-tested. The most serious risks are allergic reactions and higher blood sugar; the common ones are swelling, joint pain and numb hands. [10], [11]
- Swelling, joint pain and numb hands. Tesamorelin's label lists these as growth hormone effects (leg or foot swelling in about 6%, tingling or numbness in 4–5%); ipamorelin has not been measured. In community education groups, water retention is the most common complaint on the pair, often worse after adding ipamorelin and easing after the first weeks. [10]
- Blood sugar. On tesamorelin, 5% reached a diabetes-range HbA1c (a 3-month blood sugar average) versus 1% on placebo. In ipamorelin's one trial, high blood sugar at discharge was more common than on placebo (14.3% versus 8.6%). [10], [11]
- IGF-1 overshoot. On tesamorelin, 47% had IGF-1 (the hormone growth hormone drives) more than 2 standard deviation scores above normal for their age by 26 weeks; ipamorelin's effect on IGF-1 has never been reported. [10], [11]
- Allergic reactions. 4% had allergic reactions to tesamorelin in trials, and half made antibodies against it by 26 weeks; FDA lists immune reactions as a concern for injected ipamorelin. The label says to stop and get emergency help for swelling of the face or throat, trouble breathing or widespread hives. In community education groups, reactions on the pair cluster around restarts, dose increases and new vials; taking antihistamines to keep injecting is dangerous. [10], [21]
- Low potassium. It was more common with ipamorelin (12.5% versus 3.4%) in its one trial. [11]
- Deaths and sleep in ipamorelin's one trial. Two people on ipamorelin died after bowel surgery; FDA says it is unclear whether ipamorelin caused it. Insomnia was also more common (10.7% versus 5.2%). [11]
- Contents that do not match the label. Research vials are not EGRIFTA. Seller-posted lab results for tesa/ipa blends measured each peptide about 4% to 19% above the label, and one listing's certificate was for a different product. A compounded sermorelin and ipamorelin injection was recalled in 2021 for lack of sterility assurance. [35], [1], [14], [36], [37]
Interactions. No interaction between the two has been studied; that is missing data, not evidence of safety. Tesamorelin's label asks prescribers to watch medicines cleared by liver enzymes, such as steroids, sex hormones, seizure medicines and ciclosporin. Neither part has been tested with GLP-1 drugs, testosterone or growth hormone. [10], [11]
Be especially cautious or avoid the pair in pregnancy or breastfeeding (tesamorelin is ruled out in pregnancy); with a current or past cancer; with a damaged pituitary gland; with diabetes or prediabetes; after an allergic reaction to either part or to a related GHRH peptide; under 18; and in competitive sport. [10], [11]
Legal and sport status (checked September 2026):
- United States: tesamorelin is a prescription medicine (EGRIFTA) for excess belly fat in adults with HIV. Ipamorelin is not approved, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks. In August 2026, FDA warning letters called two tesa/ipa blends, one sold as Bimorelin, unapproved new drugs. [10], [21], [25], [6]
- Canada: no tesamorelin product is currently marketed, as both EGRIFTA listings have been cancelled; ipamorelin is unauthorized and appears in Health Canada's April 2026 list of seized injectable peptides. [38], [39]
- European Union and United Kingdom: tesamorelin was never authorized in the European Union, and no product appears in the UK medicines database. [40], [41]
- Australia: ipamorelin is prescription-only (Schedule 4) with possession restrictions, and growth-hormone-releasing hormones as a class are Schedule 4, which by our reading covers tesamorelin. [42]
- Sport: WADA prohibits both at all times, tesamorelin as a GHRH analogue and ipamorelin as a growth hormone secretagogue, on its 2026 and 2027 lists. [43], [44]
What should be monitored?
Tesamorelin's label sets what prescribers check; ipamorelin has no official guidance. Merged, the checks are:
| What to watch | Why | Tracking category |
|---|---|---|
| IGF-1 | The label suggests considering stopping if it stays above 3 standard deviation scores | Blood work |
| Fasting glucose and HbA1c, before starting and during use | Both parts raised blood sugar in trials | Blood work |
| Potassium | Low potassium was more common on ipamorelin | Blood work |
| Swelling, joint pain, hand numbness | Growth hormone effects on tesamorelin's label | Fluid Retention; Joint Health |
| Allergic and injection-site reactions | The most serious risk for both | Side Effect Burden; Skin Health |
| Eyes, in people with diabetes | The label asks for regular checks | Other |
| Waist and belly fat | The label suggests weighing whether to continue if belly fat has not fallen | Fat Loss; Weight Management |
In community education groups, educators advise testing IGF-1, fasting glucose and HbA1c before starting and again after 8–12 weeks, and deciding in advance which result would mean stopping. No study has tested that timing.
What happens when you stop?
Tesamorelin's effect on belly fat wears off after stopping. Stopping ipamorelin has not been studied, and nobody has studied stopping one part while continuing the other. [45], [11]
- Tesamorelin. In the approval trials, visceral fat returned close to its starting level within about 13 weeks of stopping, and IGF-1 fell back. Of people who had formed antibodies, 18% still had them 6 months later, which matters for anyone planning a restart. [45], [10]
- Ipamorelin. No study has looked for withdrawal effects or a rebound. After a single IV dose, growth hormone fell back within about 6 hours. [11], [29]
- Community accounts. In community education groups, water weight leaves within days, and several allergic reactions followed a restart after a break.
Premixed blend or separate vials?
A premixed vial means one injection, but it fixes the ratio, hides which part caused a side effect, and has never been tested for stability with both peptides mixed. Separate vials take more steps but keep each dose adjustable and traceable.
- Mixing and stability. No published study shows whether the two stay stable mixed in one vial or syringe; one seller of the blend advises against mixing reconstituted peptides without verified stability. Mixed EGRIFTA WR is kept at room temperature for 7 days; mixed research vials of either peptide have no tested shelf life. [46], [10], [11]
- Testing. A blend needs each peptide measured; a single "purity" figure does not show the ratio. [35]
- The ratio is locked. Tesamorelin doses are measured in milligrams and ipamorelin doses in micrograms, and the vial sets both at once. On a 6 mg + 3 mg Hulk vial, raising tesamorelin from 1 to 2 mg raises ipamorelin from 500 to 1,000 mcg, more than any single injection in the ipamorelin guide's protocols. If ipamorelin keeps you awake and you halve the dose, you also halve tesamorelin. [3], [32]
- Tracking and troubleshooting. With separate vials, a reaction can be narrowed down to one part, which is why educators in community education groups prefer them. With a blend, it cannot.
- Units. Blend doses are weights of the whole powder. "500 mcg" drawn from a 1:1 blend is 250 mcg of each, and 1 mg of a 10 mg + 3 mg blend is about 770 mcg of tesamorelin and 230 mcg of ipamorelin. Work out syringe units for your own vial with the reconstitution calculator. [47], [1]
Common questions about the tesamorelin and ipamorelin stack
Is Hulk the same as tesamorelin and ipamorelin?
At some sellers. The Hulk vial sold under one brand is 6 mg of tesamorelin with 3 mg of ipamorelin, and Hulk XL is 13 mg + 3 mg. Other sellers use the name for different peptides (see Hulk), so check each peptide's amount on the label. [3], [4], [48]
Does tesamorelin work better with ipamorelin?
Nobody has shown that it does. No study has compared the pair with tesamorelin alone. The idea comes from 1990s tests of other peptides given into a vein, and in one of them the combination released no more growth hormone than the two added together. [8], [9]
Can you mix tesamorelin and ipamorelin in one syringe?
People do, but nobody has tested whether they stay stable together. Several protocol pages describe drawing both into one bedtime injection; no published study has checked either peptide's strength after mixing. [34], [46]
Is tesa/ipa better than CJC-1295 and ipamorelin?
The two have not been compared. Both pair a GHRH-type peptide with ipamorelin. Tesamorelin is an approved, well-studied medicine; CJC-1295 is not approved, and FDA found no human studies of the version without DAC that is usually sold with ipamorelin. See the CJC-1295 and ipamorelin stack. [10], [20]
How this guide was researched
How this guide was made
This stack guide was built from the verified sources of the tesamorelin and ipamorelin guides, re-citing the original documents rather than those guides. New research covered only what the combination raises: studies of the two together, blend names and contents, seller-posted lab results, stability and regulator notices. One AI-assisted web search used public sources only, and every page cited was re-checked. Community education groups informed the descriptions of how people use the pair; no private post is quoted or linked.
The research file holds 48 records, 46 verified against the original page; this guide cites 49, including four seller pages checked for Doserly's healing and recovery, classic growth hormone releasers and CJC-1295 and ipamorelin stack guides. Seller pages are cited only for listed vial contents, never as evidence of purity or effect.
Drafting used AI assistance under Doserly's editorial rules, followed by source checks and editorial review. It is general education, not medical advice.
Explore the sources
These are the documents cited in this guide. Studies, labels, regulator pages, dosing websites and seller pages answer different questions. Seller pages and lab results are cited only for what a label says a vial contains or what one lot measured, never as proof of purity or effect. No study has tested this combination in people.
Showing 49 sources
- 01
Tesamorelin 10 mg / Ipamorelin 3 mg Blend ↗
Seller product page
Original page reviewed for listed vial contents and the seller-posted lab result (27 Jul 2026) only.
- 02
Tesamorelin + Ipamorelin Blend 5mg/10mg ↗
Seller product page
Original page reviewed; its FAQ says the 5 mg vial holds 5 mg of each peptide and the 10 mg vial 10 mg of each.
- 03
The Hulk Tesa / Ipa Blend 6/3 MG ↗
Seller product page
Original page reviewed for the name and listed vial contents only; not evidence of purity or effect.
- 04
Research peptides for sale (shop listing: Hulk XL, Hulk nasal spray and SomatoPulse) ↗
Seller listing
Original listing reviewed for product names and listed amounts only.
- 05
Phoenix Blend (Tesamorelin + Ipamorelin) ↗
Seller product page
Original page reviewed for the name and listed vial contents only; not evidence of purity or effect.
- 06
Warning letter to Royal Peptides LLC (MARCS-CMS 734884) ↗
Regulatory source
Original letter reviewed; names BIMORELIN (tesamorelin 10 mg + ipamorelin 3 mg).
- 07
Triad-GH: Tesamorelin 6 mg / Ipamorelin 3 mg / CJC-1295 no DAC 3 mg ↗
Seller product page
Original page reviewed for listed vial contents only; the seller gives no dosing guidance. Not evidence of purity or effect.
- 08
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone ↗
Human study (related peptides, IV)
Original abstract reviewed. Used GHRP-6 and GHRH(1-44), not tesamorelin or ipamorelin.
- 09
GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers ↗
Human study (related peptides, IV)
Original abstract reviewed. Used GHRP-2 and GHRH(1-29), not tesamorelin or ipamorelin.
- 10
EGRIFTA WR (tesamorelin) for injection, prescribing information ↗
Label
Original label reviewed, including dosing, warnings, adverse reactions and drug interactions.
- 11
FDA Briefing Document: Ipamorelin-Related Bulk Drug Substances ↗
Regulatory source
Original briefing reviewed, including the human-study and safety sections.
- 12
Tesamorelin + Ipamorelin Blend: Dosage & Protocol ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 13
Tesamorelin 10 mg + Ipamorelin 10 mg, 20 mg Blend ↗
Seller product page
Original page reviewed for listed vial contents only.
- 14
Lab tests: Tesamorelin & Ipamorelin 11 mg/6 mg, composition report #216357 ↗
Lab result (seller-submitted)
Original page reviewed; one seller-submitted lot, cited only for the measured amounts.
- 15
2X Blend Dosing Guide (Tesamorelin/Ipamorelin 10/5 and 5/5) ↗
Provider dosing guide
Original document reviewed for vial compositions only; its dose chart runs above the labeled tesamorelin dose and is not reproduced.
- 16
Blends: HULK Blend 10 mg Pen Kit (CJC-1295 No DAC 5 mg + Ipamorelin 5 mg) ↗
Seller listing
Original page reviewed for the name and listed contents only.
- 17
Hulk Stack (CJC-1295 with DAC & Ipamorelin), 20 mg ↗
Seller product page
Original page reviewed for the name and listed contents only; the split between the two peptides is not stated.
- 18
Hulk Stack (BPC-157 15 mg + TB-500 15 mg) ↗
Seller product page
Original page reviewed for the name and listed contents only (checked for Doserly's healing and recovery stack guide).
- 19
Tri-Blend (Phoenix): KPV / TB-500 / BPC-157 ↗
Seller product page
Original page reviewed for the name and listed vial contents only (checked for Doserly's healing and recovery stack guide).
- 20
FDA Briefing Document: CJC-1295-Related Bulk Drug Substances ↗
Regulatory source
Selected original sections reviewed (human studies; products on the market, pp. 22-23).
- 21
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗
Regulatory source
Current official page reviewed; lists ipamorelin acetate and FDA's immune-reaction concern.
- 22
Tesamorelin Protocol Guide: Dosing, Timeline & Visceral Fat Results ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 23
Tesamorelin + Ipamorelin: 1mg/300mcg Blend Dosage (2026) ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 24
Tesamorelin + Ipamorelin Peptide Stack Guide: Dosing, Reconstitution & Safety (2026) ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 25
Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) ↗
Regulatory source
Original letter reviewed; names a "Tesamorelin Ipamorelin Blend".
- 26
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men ↗
Human study (related peptides, IV)
Original abstract reviewed. Used GHRH and GHRP-2 infusions.
- 27
Tesamorelin + Ipamorelin Stack: Dosing, Benefits & Where to Buy ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 28
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data ↗
Human trials (pooled analysis)
Original abstract reviewed.
- 29
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
Human study
Original abstract reviewed.
- 30
- 31
Tesamorelin For Beginners: Benefits, Dosage, and Peptide Stacking Tips ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 32
Ipamorelin Dosage Guide: Protocols, Timing & How Much to Take (2026) ↗
Dosing website
Selected original page sections reviewed; describes practice, not a tested dose.
- 33
Tesamorelin Dosage: Units, Timing & Cycle Guide ↗
Clinic dosing page
Selected original page sections reviewed, including its tesamorelin and ipamorelin combination-vial schedule; the clinic's own convention, not a tested dose.
- 34
Tesamorelin: Benefits, Dosage & Safety ↗
Dosing website
Selected original page sections reviewed (combined protocol with ipamorelin); describes practice, not a tested dose.
- 35
Lab test TESIPA06062026-07: Tesamorelin/Ipamorelin Blend 10 mg/3 mg ↗
Lab result (seller-submitted)
Original page reviewed; one seller-submitted lot, cited only for the measured amounts.
- 36
Tesamorelin / Ipamorelin Blend 10mg / 3mg (listing and attached certificate) ↗
Seller listing and certificate
Original page reviewed; the certificate on file was issued for an ipamorelin + CJC-1295 vial, not this product.
- 37
Warning letter to Innoveix Pharmaceuticals Inc (624782) ↗
Regulatory source
Original letter reviewed, including the 2021 recall of a sermorelin and ipamorelin injection.
- 38
Drug Product Database: EGRIFTA (two product listings) ↗
Regulatory source
Records reviewed: both product registrations cancelled (2022 and 2023).
- 39
Think twice before injecting peptides bought online: unauthorized products can seriously harm you ↗
Regulatory source
Original advisory reviewed; lists ipamorelin among seized unauthorized injectable peptides.
- 40
Questions and answers on the withdrawal of the marketing authorisation application for Egrifta (tesamorelin) ↗
Regulatory source
Original document reviewed.
- 41
MHRA Products database: search for tesamorelin ↗
Regulatory source
Search result reviewed: no results for tesamorelin or Egrifta.
- 42
Poisons Standard June 2026 (F2026L00633) ↗
Regulatory source
Original text reviewed: ipamorelin entry and the growth-hormone-releasing hormones class entry. Tesamorelin is not named; applying the class entry is our reading.
- 43
WADA 2026 Prohibited List ↗
Regulatory source (sport)
Official list checked (section S2). Sport rules, not clinical evidence.
- 44
WADA 2027 Prohibited List ↗
Regulatory source (sport)
Official list checked (section S2). Sport rules, not clinical evidence.
- 45
EGRIFTA (tesamorelin) NDA 22-505 medical review ↗
Regulatory source
Selected original sections reviewed (effects after stopping).
- 46
Tesamorelin Ipamorelin Blend (handling notes) ↗
Seller product page
Original page reviewed for its storage and mixing statement only.
- 47
Tesamorelin + Ipamorelin Blend Dosage Chart Per Day & Protocol ↗
Dosing website
Original page reviewed for blend unit arithmetic only.
- 48
Hulk product listing (Tesa / Ipa Blend 6/3 mg, nasal spray and Hulk XL) ↗
Seller product listing
Original page reviewed for the name and listed contents only (checked for Doserly's classic growth hormone releasers stack guide).
- 49
Hulk Blend 10 mg/10 mg (CJC-1295 with DAC + ipamorelin) ↗
Seller product page
Original page reviewed for the name and listed vial contents only (checked for Doserly's CJC-1295 and ipamorelin stack guide).
No matching sources
Try a different term or show the full list.